Servier drug fails to slow Becker muscular dystrophy in major trial
French pharmaceutical company Servier announced Tuesday that its experimental treatment for Becker muscular dystrophy failed to show efficacy in a large placebo-controlled study.
Trial results do not match earlier data
The pivotal GRAND CANYON study did not align with findings from prior clinical research on the drug. Servier stated that the results of this Phase 3 trial were not consistent with previous observations. The company is now conducting a comprehensive analysis of the dataset to understand these findings better.
Patients lack approved treatment options
Becker muscular dystrophy patients currently have no approved treatments available for their condition. This failure represents a significant setback for both the pharmaceutical company and the patient community. The experimental drug was originally developed by Edgewise Therapeutics before Servier purchased it in June.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.